Search - tctmd.com

Displaying 81 - 100 of 140

Sort: Relevancy | Date

Presentation TCT 2015

New Randomized Trial Data (1-Year Outcomes): ABSORB III (TCT Late-Breaking Clinical Trial Results and Beyond)

Presenter: Stephen G. Ellis, Patrick W. Serruys, Dean J. Kereiakes

October 14, 2015

Presentation TCT 2015

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Vs. an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Ioanna Kosmidou, Dean J. Kereiakes

October 12, 2015

Presentation TCT 2015

BIOSOLVE II: Evaluation of a Sirolimus-Eluting Bioresorbable Metallic Scaffold Six-Month Clinical, Angiographic, and Imaging Outcomes

Presenter: Dean J. Kereiakes, Ron Waksman, Davide Capodanno, Michael Haude

October 12, 2015

Presentation TCT 2015

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Gregg W. Stone, Ron Waksman, Dean J. Kereiakes

October 12, 2015

News Conference News TCT 2015

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

Yael L. Maxwell

October 12, 2015

News Industry News

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

October 12, 2015

Presentation TCT 2015

Everolimus-Eluting Bioabsorbable-Polymer DES Outcomes: SYNERGY Update

Presenter: Stephen G. Ellis, John A. Ormiston, Dean J. Kereiakes

October 11, 2015

News Daily News

ITALIC Published: No Benefit to Long-Term DAPT After Stenting

Yael L. Maxwell

March 10, 2015

News Conference News AHA 2014

Biodegradable-Polymer DES Perform Well But Appear No Safer than Their Durable-Polymer Counterparts

November 18, 2014

News Industry News

New Data From EVOLVE Clinical Program Demonstrate SYNERGY™ Bioabsorbable Polymer Stent Meets Key Performance Endpoints

November 18, 2014

Presentation AHA 2014

Primary Outcomes of the EVOLVE II Trial: A Prospective Randomized Investigation of a Novel Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent

Presenter: Dean J. Kereiakes

November 16, 2014

Presentation TCT 2014

BRS Under Development V Biolute BRS

Presenter: Alexandre Abizaid, Dean J. Kereiakes, Vasim Farooq, Dinesh Shah

September 16, 2014

Presentation TCT 2014

BRS Under Development IV The Lepu BRS

Presenter: Alexandre Abizaid, Dean J. Kereiakes, Vasim Farooq, Yaling Han

September 16, 2014

Presentation TCT 2014

BRS Under Development III The XINSORB BRS

Presenter: Alexandre Abizaid, Dean J. Kereiakes, Vasim Farooq, Junbo Ge

September 16, 2014

Presentation TCT 2014

BRS Under Development II Meril Life Sciences

Presenter: Alexandre Abizaid, Dean J. Kereiakes, Vasim Farooq, Martin B. Leon

September 16, 2014

Presentation TCT 2014

BRS Under Development I The Manli Mirage BRS

Presenter: Alexandre Abizaid, Dean J. Kereiakes, Vasim Farooq, Teguh Santoso

September 16, 2014

Presentation TCT 2014

BRS with Clinical Data V DREAMS: Differentiating Features and Clinical Update

Presenter: Alexandre Abizaid, Dean J. Kereiakes, Vasim Farooq, Michael Haude

September 16, 2014

Presentation TCT 2014

BRS with Clinical Data IV ART-DIVA: Differentiating Features and Clinical Update

Presenter: Alexandre Abizaid, Dean J. Kereiakes, Vasim Farooq, Jean Fajadet

September 16, 2014

Presentation TCT 2014

BRS with Clinical Data III Amaranth: Differentiating Features and Clinical Update

Presenter: Alexandre Abizaid, Dean J. Kereiakes, Vasim Farooq, Juan F. Granada

September 16, 2014

Presentation TCT 2014

BRS with Clinical Data II From ReSolve to Fantom: Differentiating Features and Clinical Update

Presenter: Alexandre Abizaid, Dean J. Kereiakes, Vasim Farooq

September 16, 2014

Advertisement

New Randomized Trial Data (1-Year Outcomes): ABSORB III (TCT Late-Breaking Clinical Trial Results and Beyond)

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Vs. an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

BIOSOLVE II: Evaluation of a Sirolimus-Eluting Bioresorbable Metallic Scaffold Six-Month Clinical, Angiographic, and Imaging Outcomes

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

Everolimus-Eluting Bioabsorbable-Polymer DES Outcomes: SYNERGY Update

ITALIC Published: No Benefit to Long-Term DAPT After Stenting

Biodegradable-Polymer DES Perform Well But Appear No Safer than Their Durable-Polymer Counterparts

New Data From EVOLVE Clinical Program Demonstrate SYNERGY™ Bioabsorbable Polymer Stent Meets Key Performance Endpoints

Primary Outcomes of the EVOLVE II Trial: A Prospective Randomized Investigation of a Novel Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent

BRS Under Development V Biolute BRS

BRS Under Development IV The Lepu BRS

BRS Under Development III The XINSORB BRS

BRS Under Development II Meril Life Sciences

BRS Under Development I The Manli Mirage BRS

BRS with Clinical Data V DREAMS: Differentiating Features and Clinical Update

BRS with Clinical Data IV ART-DIVA: Differentiating Features and Clinical Update

BRS with Clinical Data III Amaranth: Differentiating Features and Clinical Update

BRS with Clinical Data II From ReSolve to Fantom: Differentiating Features and Clinical Update

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content